Drug Name: Spevigo Active Ingredient: spesolimab-sbzo Indications: To treat generalized pustular psoriasis flares Approval Date: 9/1/2022 Company: Boehringer Ingelheim International GmbH Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761244s000lbl.pdf
Drug Name: Xenpozyme Active Ingredient: Olipudase alfa Indications: To treat Acid Sphingomyelinase Deficiency (ASD) Approval Date: 8/31/2022 Company: Genzyme Corporation Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761261s000lbl.pdf
Drug Name: Amvuttra Active Ingredient: vutrisiran Indications: To treat polyneuropathy of hereditary transthyretin-mediated amyloidosis Approval Date: 6/13/2022 Company: Alnylam Pharmaceuticals, Inc Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215515s000lbl.pdf
Drug Name: Vtama Active Ingredient: tapinarof Indications: To treat plaque psoriasis Approval Date: 5/23/2022 Company: Dermavant Sciences Inc, Dermavant Sciences, GmbH Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215272s000lbl.pdf
Drug Name: Mounjaro Active Ingredient: tirzepatide Indications: To improve blood sugar control in diabetes, in addition to diet and exercise Approval Date: 5/13/2022 Company: Eli Lilly and Company Learn more: …
Drug Name: Voquezna Active Ingredient: vonoprazan, amoxicillin, and clarithromycin Indications: To treat Helicobacter pylori infection Approval Date: 5/3/2022 Company: Phathom Pharmaceuticals, Inc. More: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215152s000,215153s000lbl.pdf
Drug Approval Name: Camzyos Active Ingredient: mavacamten Indications: To treat certain classes of obstructive hypertrophic cardiomyopathy Approval Date: 4/28/2022 Company: MyoKardia, Inc., a wholly-owned subsidiary of Bristol Myers Squibb More: …
Drug Name: Vivjoa Active Ingredient: oteseconazole Indications: To reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are not of reproductive potential Approval…
Drug Name: Pluvicto Active Ingredient: lutetium (177Lu) vipivotide tetraxetan Indications: To treat prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer following other therapies Approval Date: 3/23/2022 Company: Advanced Accelerator Applications USA,…
Drug Approval Name: Ztalmy Indications: To treat seizures in cyclin-dependent kinase-like 5 deficiency disorder Active Ingredient: ganaxolone Company: Marinus Pharmaceuticals, Inc. Approval Date: 3/18/2022 Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215904s000lbl.pdf